News & Updates
Filter by Specialty:
Tenofovir in mothers plus HBIG in infants best prevent vertical HBV transmission
For mothers with hepatitis B virus (HBV) infection who are positive for both hepatitis B surface and envelope antigens, administering a combination of hepatitis B vaccine and immunoglobulin (HBIG) in their infants plus tenofovir disoproxil fumarate (TDF) in the mothers themselves appears to be the best approach for preventing vertical disease transmission, according to a study.
Tenofovir in mothers plus HBIG in infants best prevent vertical HBV transmission
07 Aug 2022Overweight, obesity do not worsen disease activity for children with IBD
In children with newly diagnosed inflammatory bowel disease (IBD), overweight and obese status are not associated with worse disease activity at 1 year after diagnosis compared with normal weight, results of a study have shown.
Overweight, obesity do not worsen disease activity for children with IBD
05 Aug 2022RATIONALE-208 subanalyses boost tislelizumab potential for HCC
The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.
RATIONALE-208 subanalyses boost tislelizumab potential for HCC
05 Aug 2022Conversion to resectability uncommon in trials of unresectable mCRC patients
In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.
Conversion to resectability uncommon in trials of unresectable mCRC patients
04 Aug 2022Drinking sugar-sweetened beverages detrimental to gut
People who consume sugar-sweetened beverages, rather than artificially sweetened beverages or natural juices, are at increased risk of developing inflammatory bowel disease, especially Crohn’s disease, as reported in a study.
Drinking sugar-sweetened beverages detrimental to gut
04 Aug 2022Earlier anti-TNF-α medication helps ensure treatment success in paediatric IBD
First-line treatment with tumour necrosis factor-α (TNF-α) blockers is both safe and effective in children with inflammatory bowel disease (IBD), according to a recent study. Early drug initiation even cuts the likelihood of treatment failure and leads to fewer extraintestinal symptoms.
Earlier anti-TNF-α medication helps ensure treatment success in paediatric IBD
02 Aug 2022HBV coinfection among TB patients higher than expected
Coinfection with hepatitis B virus (HBV) among patients with tuberculosis (TB) appears to be 38-percent to 450-percent more prevalent than published estimates from the Polaris group of region-specific overall HBV prevalence, suggest the results of a meta-analysis.